MA40530A - Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate - Google Patents
Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamateInfo
- Publication number
- MA40530A MA40530A MA040530A MA40530A MA40530A MA 40530 A MA40530 A MA 40530A MA 040530 A MA040530 A MA 040530A MA 40530 A MA40530 A MA 40530A MA 40530 A MA40530 A MA 40530A
- Authority
- MA
- Morocco
- Prior art keywords
- glutamate receptor
- metabotropic glutamate
- allosteric modulator
- chromone oxime
- glutamate
- Prior art date
Links
- IPDGWIYTNQXKSP-UHFFFAOYSA-N n-chromen-4-ylidenehydroxylamine Chemical compound C1=CC=C2C(=NO)C=COC2=C1 IPDGWIYTNQXKSP-UHFFFAOYSA-N 0.000 title abstract 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
- 229940125516 allosteric modulator Drugs 0.000 title 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- 229930195712 glutamate Natural products 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000009206 glutamatergic signaling Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Physiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne un nouveau dérivé d'oxime de chromone de formule (i), qui est un modulateur de récepteurs du système nerveux sensibles au glutamate et, en outre, qui présente une pénétration avantageusement élevée dans le cerveau lors de l'administration par voie orale. L'invention concerne également une composition pharmaceutique contenant ce composé et son utilisation pour le traitement ou la prévention d'états de santé associés à une signalisation et/ou des fonctions glutamatergiques modifiées ou d'états de santé pouvant être influencés par la modification du taux ou de la signalisation du glutamate, en particulier des troubles neurologiques et/ou psychiatriques aigus et chroniques.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14182468 | 2014-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40530A true MA40530A (fr) | 2017-07-05 |
Family
ID=51421865
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040530A MA40530A (fr) | 2014-08-27 | 2015-08-27 | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| MA052702A MA52702A (fr) | 2014-08-27 | 2015-08-27 | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| MA048048A MA48048A (fr) | 2014-08-27 | 2015-08-27 | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052702A MA52702A (fr) | 2014-08-27 | 2015-08-27 | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| MA048048A MA48048A (fr) | 2014-08-27 | 2015-08-27 | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10017521B2 (fr) |
| EP (3) | EP3186257B1 (fr) |
| JP (1) | JP6430015B2 (fr) |
| KR (1) | KR101870589B1 (fr) |
| CN (2) | CN110343118A (fr) |
| AU (1) | AU2015308438B2 (fr) |
| CA (1) | CA2956191C (fr) |
| CY (1) | CY1121352T1 (fr) |
| DK (1) | DK3186257T3 (fr) |
| ES (1) | ES2714073T3 (fr) |
| HR (1) | HRP20190343T1 (fr) |
| HU (1) | HUE041941T2 (fr) |
| IL (1) | IL250287B (fr) |
| LT (1) | LT3186257T (fr) |
| MA (3) | MA40530A (fr) |
| ME (1) | ME03339B (fr) |
| MX (1) | MX369643B (fr) |
| NZ (1) | NZ728853A (fr) |
| PL (1) | PL3186257T3 (fr) |
| PT (1) | PT3186257T (fr) |
| RS (1) | RS58592B1 (fr) |
| RU (1) | RU2672569C2 (fr) |
| SI (1) | SI3186257T1 (fr) |
| SM (1) | SMT201900152T1 (fr) |
| TR (1) | TR201903332T4 (fr) |
| WO (1) | WO2016030444A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3186257B1 (fr) * | 2014-08-27 | 2019-02-06 | Prexton Therapeutics SA | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| PT3341380T (pt) * | 2015-08-27 | 2019-12-19 | Prexton Therapeutics Sa | Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa |
| KR20210039368A (ko) | 2018-07-26 | 2021-04-09 | 도메인 테라퓨틱스 | 치환된 퀴나졸리논 유도체 및 mGluR4의 양성 알로스테릭 조절인자로서의 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4065467A (en) | 1973-12-27 | 1977-12-27 | Carlo Erba, S. P. A. | 5:6-Benzo δ-pyrone derivatives and process for their preparation |
| US4777252A (en) | 1987-08-13 | 1988-10-11 | E. R. Squibb & Sons, Inc. | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines |
| JP3993651B2 (ja) * | 1994-10-21 | 2007-10-17 | アスビオファーマ株式会社 | シクロプロパクロメンカルボン酸誘導体 |
| EP1298129A3 (fr) | 2001-09-28 | 2003-06-04 | Central Glass Company, Limited | Procédé pour la préparation de dérivés the Benzopyran substitués en position 4 |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| AU2004230841A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US20070027216A1 (en) | 2005-07-15 | 2007-02-01 | Bridget Larson | Novel hydrochloride salts of levodopa |
| GB0713686D0 (en) | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| JP2010533147A (ja) | 2007-07-13 | 2010-10-21 | アデックス ファルマ エス．エイ． | 代謝調節型グルタミン酸レセプターのモジュレーターとしてのピラゾール誘導体 |
| EP2493871B1 (fr) | 2009-10-30 | 2014-09-03 | Domain Therapeutics | Nouveaux dérivés d'oxime et leur utilisation en tant que modulateurs allostériques de récepteurs du glutamate métabotropique |
| SG10201510665WA (en) | 2009-12-04 | 2016-01-28 | Sunovion Pharmaceuticals Inc | Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders |
| EP2804870B1 (fr) * | 2012-01-18 | 2016-11-30 | ADDEX Pharma S.A. | 2-amino-4,5,6,8-tétrahydropyrazolo[3,4-b]thiazolo[4,5-d]azépine et leur utilisation comme modulateurs allostériques des récepteurs métabotropiques au glutamate |
| EP3186257B1 (fr) * | 2014-08-27 | 2019-02-06 | Prexton Therapeutics SA | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate |
| PT3341380T (pt) | 2015-08-27 | 2019-12-19 | Prexton Therapeutics Sa | Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa |
-
2015
- 2015-08-27 EP EP15770814.0A patent/EP3186257B1/fr active Active
- 2015-08-27 CA CA2956191A patent/CA2956191C/fr not_active Expired - Fee Related
- 2015-08-27 MA MA040530A patent/MA40530A/fr unknown
- 2015-08-27 MA MA052702A patent/MA52702A/fr unknown
- 2015-08-27 MX MX2017002429A patent/MX369643B/es active IP Right Grant
- 2015-08-27 PT PT15770814T patent/PT3186257T/pt unknown
- 2015-08-27 PL PL15770814T patent/PL3186257T3/pl unknown
- 2015-08-27 ES ES15770814T patent/ES2714073T3/es active Active
- 2015-08-27 SI SI201530640T patent/SI3186257T1/sl unknown
- 2015-08-27 CN CN201910567865.9A patent/CN110343118A/zh active Pending
- 2015-08-27 HU HUE15770814A patent/HUE041941T2/hu unknown
- 2015-08-27 WO PCT/EP2015/069601 patent/WO2016030444A1/fr not_active Ceased
- 2015-08-27 MA MA048048A patent/MA48048A/fr unknown
- 2015-08-27 AU AU2015308438A patent/AU2015308438B2/en not_active Ceased
- 2015-08-27 TR TR2019/03332T patent/TR201903332T4/tr unknown
- 2015-08-27 HR HRP20190343TT patent/HRP20190343T1/hr unknown
- 2015-08-27 ME MEP-2019-59A patent/ME03339B/fr unknown
- 2015-08-27 NZ NZ728853A patent/NZ728853A/en not_active IP Right Cessation
- 2015-08-27 JP JP2017530425A patent/JP6430015B2/ja not_active Expired - Fee Related
- 2015-08-27 RU RU2017109818A patent/RU2672569C2/ru active
- 2015-08-27 EP EP19151429.8A patent/EP3502115A1/fr not_active Withdrawn
- 2015-08-27 US US15/506,941 patent/US10017521B2/en not_active Expired - Fee Related
- 2015-08-27 EP EP19217991.9A patent/EP3696183A1/fr not_active Withdrawn
- 2015-08-27 DK DK15770814.0T patent/DK3186257T3/en active
- 2015-08-27 CN CN201580045432.7A patent/CN106715444B/zh not_active Expired - Fee Related
- 2015-08-27 LT LTEP15770814.0T patent/LT3186257T/lt unknown
- 2015-08-27 SM SM20190152T patent/SMT201900152T1/it unknown
- 2015-08-27 RS RS20190289A patent/RS58592B1/sr unknown
- 2015-08-27 KR KR1020177005768A patent/KR101870589B1/ko not_active Expired - Fee Related
-
2017
- 2017-01-25 IL IL250287A patent/IL250287B/en active IP Right Grant
-
2018
- 2018-06-05 US US16/000,338 patent/US10442818B2/en active Active
-
2019
- 2019-03-08 CY CY20191100277T patent/CY1121352T1/el unknown
- 2019-09-30 US US16/587,670 patent/US20200024285A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2019000126A1 (fr) | Nouvelles compositions antivirales pour le traitement des infections liées aux coronavirus. | |
| MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
| MA41562A1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
| MA54229B1 (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| MA35753B1 (fr) | Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2 | |
| EP3207931A3 (fr) | Effet protecteur de dmpc, dmpg, dmpc/dmpg, egpg, lysopg et lysopc contre les médicaments provoquant des canalopathies | |
| MA45782B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA33569B1 (fr) | Ligands sigma pour la prevention ou le traitement de la douleur induite par la chimiotherapie | |
| MA35611B1 (fr) | Composé inhibiteur de la signalisation par la voie notch | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA31700B1 (fr) | Derives d'azacyclylisoquinolinone et -isoindolinone servant d'antagonistes du recepteur d'histamine-3 | |
| FR3065642B1 (fr) | Utilisation de 20-hydroxyecdysone et ses derives dans le traitement des myopathies | |
| EP3700525A4 (fr) | Administration améliorée d'antioxydants pour le traitement de troubles du système nerveux central impliquant un stress oxydatif | |
| MA40865B1 (fr) | Thiazoles à substitution amide utilisés comme modulateurs de rorgammat | |
| MA42700B1 (fr) | Dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate | |
| MA40530A (fr) | Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| TN2016000040A1 (fr) | Inhibiteurs de porc2 et procedes pour leur utilisation | |
| MA40863A (fr) | Thiazoles en tant que modulateurs de roryt | |
| MA34806B1 (fr) | Compositions pharmaceutiques | |
| MA38679A1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
| MA34314B1 (fr) | Préparation de paracétamol injectable stable, prête à l'emploi | |
| MA39253B1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
| FR3033701B1 (fr) | Nouvelles compositions antivirales pour le traitement de la grippe |